1. Medicines
  2. Haematology
  3. SCEMBLIX®▼ (asciminib)
  4. Mechanism of action

Prescribing information

 

The below content is for healthcare professionals in Great Britain only. If you require information for Northern Ireland please refer to the Northern Ireland prescribing information.

 

Mechanism of action (MOA)

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

SCEMBLIX®▼(asciminib) is the first and only STAMP inhibitor1–3

Learn how the unique MOA of SCEMBLIX enhances its specificity in treating CML.1

SCEMBLIX targets a different site on BCR-ABL1 – the myristoyl pocket1-3

 

In people who do not have CML, the myristoyl pocket is occupied by the N-terminal portion of ABL1, maintaining the protein in an inactive conformation.4,5

In BCR-ABL1, the myristoyl pocket is vacant, activating the kinase.4,5

Image showing the MOA of Scemblix

SCEMBLIX is a first-in-class STAMP inhibitor. Binding specifically to the myristoyl pocket, it potently inactivates BCR-ABL1 via allosteric inhibition.1

With its unique MOA, SCEMBLIX offers a different approach for treating CML.4–6

Learn about the efficacy of SCEMBLIX

EXPLORE THE DATA

ATP, adenosine triphosphate; CML, chronic myeloid leukaemia; MOA, mechanism of action; STAMP, specifically targeting the ABL1 myristoyl pocket; TKI, tyrosine kinase inhibitor.

SCEMBLIX is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.7

For further information please refer to the Summary of Product Characteristics.

 

References

  1. Réa D, et al. Blood 2021;138(21):2031–2041.
  2. Redaelli S, et al. J Clin Oncol 2009;27(3):469–471.
  3. Schoepfer J, et al. J Med Chem 2018;61(18):8120–8135.
  4. Hughes TP, et al. N Engl J Med 2019;381(24):2315–2326.
  5. Manley PW, et al. Leuk Res 2020;98:106458.
  6. Iacob RE, et al. PLoS One 2011;6(1):e15929.
  7. SCEMBLIX (asciminib) Summary of Product Characteristics.
Rate this content: 
Average: 5 (1 vote)
UK | October 2022 | 212211
Haematology
Article

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com